249 related articles for article (PubMed ID: 15143081)
21. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group.
Ohno R; Tomonaga M; Ohshima T; Masaoka T; Asou N; Oh H; Nishikawa K; Kanamaru A; Murakami H; Furusawa S
Int J Hematol; 1993 Aug; 58(1-2):73-81. PubMed ID: 7693029
[TBL] [Abstract][Full Text] [Related]
22. Can EPO reduce blood transfusion requirements during induction therapy for high-risk neuroblastoma?
Cazzola M
Nat Clin Pract Oncol; 2004 Nov; 1(1):22-3. PubMed ID: 16264794
[No Abstract] [Full Text] [Related]
23. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
24. A case-control retrospective study of the efficacy of granulocyte-colony-stimulating factor in children with neuroblastoma.
Housholder SE; Rackoff WR; Goldman J; Breitfeld PP
Am J Pediatr Hematol Oncol; 1994 May; 16(2):132-7. PubMed ID: 7513135
[TBL] [Abstract][Full Text] [Related]
25. Circulation of progenitor cells after intensive chemotherapy followed by combination G-CSF and EPO in breast carcinoma.
Filip S; Vanásek J; Bláha M; Vávrová J
Neoplasma; 1997; 44(4):212-8. PubMed ID: 9473775
[TBL] [Abstract][Full Text] [Related]
26. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
Watanabe T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
[TBL] [Abstract][Full Text] [Related]
27. Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation.
Locatelli F; Zecca M; Ponchio L; Beguin Y; Giorgiani G; Maccario R; Bonetti F; De Stefano P; Cazzola M
Bone Marrow Transplant; 1994 Dec; 14(6):929-35. PubMed ID: 7536073
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
29. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
31. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
33. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study.
Bönig H; Silbermann S; Weller S; Kirschke R; Körholz D; Janssen G; Göbel U; Nürnberger W
Bone Marrow Transplant; 2001 Aug; 28(3):259-64. PubMed ID: 11535993
[TBL] [Abstract][Full Text] [Related]
34. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
35. [Kinetics of myelopoietic regeneration and mobilization of CD34-positive cells within the scope of the NB90 Neuroblastoma Therapy Study].
Sauter S; Bauer J; Berner R; Duffner U; Niemeyer C
Klin Padiatr; 1997; 209(4):191-5. PubMed ID: 9340428
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
37. Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study.
Peters-Engl C; Medl M; Denison U; Sevelda P; Leodolter S; Petru E
Anticancer Res; 2001; 21(5):3701-6. PubMed ID: 11848547
[TBL] [Abstract][Full Text] [Related]
38. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
Valteau-Couanet D; Faucher C; Aupérin A; Michon J; Milpied N; Boiron JM; Bourhis JH; Gisselbrecht C; Vernant JP; Pinna A; Bendahmane B; Delabarre F; Benhamou E
Bone Marrow Transplant; 2005 Sep; 36(6):547-52. PubMed ID: 16007101
[TBL] [Abstract][Full Text] [Related]
40. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period.
Hornedo J; Solá C; Solano C; López JJ; Alonso S; Lluch A; Ojeda B; Garcia-Conde J; Cortés-Funes H;
Bone Marrow Transplant; 2002 May; 29(9):737-43. PubMed ID: 12040470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
